KPTI
Karyopharm Therapeutics Inc
1.80$
-3.3%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22,465.9% | -37,611.6% | -54,799.4% | -4,593.0% | -524.5% | -466.6% | -148.2% | -51.1% | -95.2% | -63.5% | -87.8% | -51.6% | |
| 141.0% | 253.6% | 465.6% | 44.4% | 2.4% | 2.4% | 0.9% | 0.4% | 0.4% | 0.4% | 0.2% | -0.1% | |
| 6,218.3% | 6,822.8% | 14,469.5% | 1,271.3% | 56.9% | 37.4% | 22.6% | 14.2% | 22.5% | 14.9% | 12.7% | 9.6% | |
| 6,240.2% | 6,822.8% | 14,469.5% | 1,271.3% | 56.9% | 37.4% | 22.4% | 17.6% | 22.4% | – | – | – | |
| 4,242.4% | 1,599.2% | 640.9% | 2,053.7% | -0.6% | -32.5% | 1.3% | -11.1% | -12.7% | 21.5% | -0.2% | 19.4% | |
| 1,237.6% | 566.4% | 45.5% | 3.9% | 7.8% | 0.5% | 0.1% | 2.7% | 0.1% | 0.0% | 0.1% | 0.0% | |
| -29,271.2% | -36,329.2% | 15,970.8% | 1,065.9% | -354.9% | 191.8% | -49.7% | 67.6% | -66.4% | 5.4% | 65.7% | 29.7% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 49,397.8% | 246.4% | 409.1% | 53.5% | 11.6% | 11.0% | 9.5% | 1.8% | 2.5% | – | 76.4% | – | |
| – | 66,754.0% | 108,366.9% | 10,397.8% | 550.1% | – | – | – | 0.0% | 0.0% | 57.4% | 18.5% | |
| 49,397.8% | 37,080.0% | 33,223.4% | 4,719.2% | 1,042.0% | 304.0% | 159.2% | 35.1% | 123.3% | 0.8% | 28.7% | 20.6% | |
| -2,342.8% | -36,900.4% | -5,646.1% | 1,204.6% | 162.3% | 29.2% | -38.5% | 51.6% | -38.6% | -57.3% | 6.6% | -1.3% | |
| -23,703.5% | -38,178.0% | -54,844.8% | -4,596.8% | -532.3% | -467.1% | -148.4% | -53.8% | -95.3% | -63.5% | -87.9% | -51.6% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.